Antitumor Activity of Lysophosphatidic Acid Acyltransferase-β Inhibitors, a Novel Class of Agents, in Multiple Myeloma

Cancer Research

Volumn 63, Issue 23, 2003, Pages 8428-8436

  Hideshima, Teru ^a   Chauhan, Dharminder ^a   Hayashi, Toshiaki ^a   Podar, Klaus ^a   Akiyama, Masaharu ^a   Mitsiades, Constantine ^a   Mitsiades, Nicholas ^a   Gong, Baoqing ^b   Bonham, Lynn ^b   De Vries, Peter ^b   Munshi, Nikhil ^a   Richardson, Paul G ^a   Singer, Jack W ^b   Anderson, Kenneth C ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Cell Therapeutics Inc   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CASPASE 3; CASPASE 7; CASPASE 8; CT 32176; CT 32458; CT 32615; DEXAMETHASONE; GLYCEROL 3 PHOSPHATE ACYLTRANSFERASE; GLYCEROL 3 PHOSPHATE ACYLTRANSFERASE INHIBITOR; INTERLEUKIN 6; LYSOPHOSPHATIDIC ACID ACYLTRANSFERASE BETA INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; SOMATOMEDIN C; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNOMODULATION; MULTIPLE MYELOMA; PRIORITY JOURNAL; TUMOR GROWTH;

ACYLTRANSFERASES; ANTINEOPLASTIC AGENTS; CASPASE 3; CASPASE 7; CASPASES; CELL LINE, TUMOR; DEXAMETHASONE; ENZYME INHIBITORS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INTERLEUKIN-6; ISOENZYMES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE KINASE 4; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MULTIPLE MYELOMA; NF-KAPPA B; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 10744221197     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Gregory, W. M., Richards, M. A., and Malpas, J. S. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J. Clin. Oncol., 10: 334-342, 1992.
2. Group, M. T. S. C. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J. Clin. Oncol., 16: 3832-3842, 1998.
3. Fermand, J. P., Ravaud, P., Chevret, S., Divine, M., Leblond, V., Belanger, C., Macro, M., Pertuiset, E., Dreyfus, F., Mariette, X., Boccacio, C., and Brouet, J. C. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood, 92: 3131-3136, 1998.
4. Lenhoff, S., Hjorth, M., Holmberg, E. I. T., Westin, J., Nielsen, J. L., Wisloff, F., Brinch, L., Carlson, K., Carlsson, M., Dahl, I-M., Gimsing, P., Hippe, E., Johnsen, H., Lamvik, J., Lofvenberg, E., Nesthus, I., and Rodjer, S. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Blood, 95: 7-11, 2000.
5. Attal, M., and Harousseau, J. L. Randomized trial experience of the Intergroupe Francophone du Myelome. Semin. Hematol., 38: 226-230, 2001.
6. Salmon, S. E., Dalton, W. S., Grogan, T. M., Plezia, P., Lehnert, M., Roe, D. J., and Miller, T. P. Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood, 78: 44-50, 1991.
7. Grogan, T. M., Spier, C. M., Salmon, S. E., Matzner, M., Rybski, J., Weinstein, R. S., Scheper, R. J., and Dalton, W. S. P-Glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood, 81: 490-495, 1993.
8. Sonneveld, P., Lokhorst, H. M., and Vossebeld, P. Drug resistance in multiple myeloma. Semin. Hematol., 34: 34-39, 1997.
9. Covelli, A. Modulation of multidrug resistance (MDR) in hematological malignancies. Ann. Oncol., 10: 53-59, 1999.
10. Schwarzenbach, H. Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma. Med. Oncol., 19: 87-104, 2002.
11. Damiano, J. S., Cress, A. E., Hazlehurst, L. A., Shtil, A. A., and Dalton, W. S. Cell adhesion-mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood, 93: 1658-1667, 1999.
12. Hazlehurst, L. A., Damiano, J. S., Buyuksal, I., Pledger, W. J., and Dalton, W. S. Adhesion to fibronectin via β1 integrins regulates p27kip I levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene, 19: 4319-4327, 2000.
13. Tu, Y., Gardner, A., and Lichtenstein, A. The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. Cancer Res., 60: 6763-6770, 2000.
14. Hideshima, T., Nakamura, N., Chauhan, D., and Anderson, K. C. Biologic sequelae of interleukin-6 induced P13-K/Akt signaling in multiple myeloma. Oncogene, 20: 5991-6000, 2001.
15. Mitsiades, C. S., Mitsiades, N., Kung, A. L., Shringapurne, R., Poulaki, V., Richardson, P. G., Libermann, T. A., Munshi, N. C., Loukopoulos, D., and Anderson, K. C. The 1GF/IGF-IR system is a major therapeutic target for multiple myeloma, other hematologic malignancies and solid tumors. Blood, 100: 170a, 2002.
16. Hideshima, T., and Anderson, K. C. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat. Rev. Cancer, 2: 927-937, 2002.
17. Richardson, P. G., Berenson, J., Irwin, D., Jagannath, S., Traynor, A. E., Rajikumar, V. J., Alsina, M., Kuter, D., Siegel, D., Barlogie, B., Alexanian, R., Orlowski, R., Esseltine, D., Kauffman, M., Adams, J., Schenkein, D. P., and Anderson, K. C. Phase II trial of PS-341, a novel proteasome inhibitor, alone or in combination with dexamethasone, in patients with multiple myeloma who have relapsed following front-line therapy and are refractory to their most recent therapy. Blood, 98: 774a, 2001.
18. Richardson, P., Jagannath, S., Schlosman, R., Weller, E., Zeldenrust, S., Rajkumar, S. V., Alsina, M., Desikan, R. K., Mitsiades, C., Kelly, K., Doss, D., McKenny, M., Shepard, T., Rich, R., Warren, D., Freman, A., Deocampo, R., Doucet, K., Knight, R., Balinski, K., Zeldis, J., Dalton, W. S., Hideshima, T., and Anderson, K. A multicenter randomized, Phase II study to evaluate the efficacy and safety of two CDC-5013 dose regimens when used alone or in combination with dexamethasone (Dex) for the treatment of relapsed and refractory multiple myeloma. Blood, 100: 104a, 2002.
19. Richardson, P., Schlosman, R., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L., Doss, D., Kelly, K. A., MvKenney, M., Mechlowicz, J., Freeman, A., Decampo, R., Rich, R., Ryoo, J., Chauhan, D., Balinski, K., Zeldis, J., and Anderson, K. C. Immunomodulatory derivative of thalidomide CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, 100: 3063-3067, 2002.
20. Aguado, B., and Campbell, R. D. Characterization of a human lysophosphatidic acid acyltransferase that is encoded by a gene located in the class III region of the human major histocompatibility complex. J. Biol. Chem., 273: 4096-4105, 1998.
21. Abraham, E., Bursten, S., Shenkar, R., Allbee, J., Tuder, R., Woodson, P., Guidot, D. M., Rice, G., Singer, J. W., and Repine, J. E. Phosphatidic acid signaling mediates lung cytokine expression and lung inflammatory injury after hemorrhage in mice. J. Exp. Med., 181: 569-575, 1995.
22. Coon, M., Ball, A., Pound, J., Ap, S., de Vries, P., Tulinski, J., and Singer, J. W. RNAi knockdown of lysophosphatidic acid acyltransferase-β (LPAAT-β) activity disrupts RAS-RAF-ERK and P13-K/mTOR pathways and selectively induces tumor cell apoptosis. Blood, 100: 191a, 2002.
23. Hideshima, T., Richardson, P., Chauhan, D., Palombella, V. J., Elliot, P. J., Adams, J., and Anderson, K. C. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma. Cancer Res., 61: 3071-3076, 2001.
24. Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F. E., Tai, Y. T., Treon, S. P., Lin, B., Schlossman, R. L., Richardson, P., Muller, G., Stirling, D. I., and Anderson, K. C. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood, 96: 2943-2950, 2000.
25. Klein, B., Zhang, X. G., Lu, Z. Y., and Bataille, R. Interleukin-6 in human multiple myeloma. Blood, 85: 863-872, 1995.
26. Lichtenstein, A., Tu, Y., Fady, C., Vescio, R., and Berenson, J. Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol., 162: 248-255, 1995.
27. Ogata, A., Chauhan, D., Teoh, G., Treon, S. P., Urashima, M., Schlossman, R. L., and Anderson, K. C. Interleukin-6 triggers cell growth via the ras-dependent mitogen-activated protein kinase cascade. J. Immunol., 159: 2212-2221, 1997.
28. Chauhan, D., Kharbanda, S., Ogata, A., Urashima, M., Teoh, G., Robertson, M., Kufe, D. W., and Anderson, K. C. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood, 89: 227-234, 1997.
29. Chauhan, D., Pandey, P., Ogata, A., Teoh, G., Krett, N., Halgren, R., Rosen, S., Kufe, D., Kharbanda, S., and Anderson, K. Cytochrome c-dependent and -independent induction of apoptosis in multiple myeloma cells. J. Biol. Chem., 272: 29995-29997, 1997.
30. Chauhan, D., Hideshima, T., Pandey, P., Treon, S., Teoh, G., Raje, N., Rosen, S., Krett, N., Husson, H., Avraham, S., Kharbanda, S., and Anderson, K. C. RAFTK/ PYK2-dependent and -independent apoptosis in multiple myeloma cells. Oncogene, 18: 6733-6740, 1999.
31. Chauhan, D., Pandey, P., Hideshima, T., Treon, S., Raje, N., Davies, F. E., Shima, Y., Tai, Y. T., Rosen, S., Avraham, S., Kharbanda, S., and Anderson, K. C. SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J. Biol. Chem., 275: 27845-27850, 2000.
32. Hideshima, T., Chauhan, D., Teoh, G., Raje, N., Treon, S. P., Tai, Y-T., Shima, Y., and Anderson, K. C. Characterization of signaling cascades triggered by human interleukin-6 versus Kaposi's sarcoma-associated herpes virus-encoded viral interleukin-6. Clin. Cancer Res., 6: 1180-1189, 2000.
33. Freund, G. G., Kulas, D. T., and Mooney, R. A. Insulin and 1GF-I increase mitogenesis and glucose metabolism in the multiple myeloma cell line, RPMI 8226. J. Immunol., 151: 1811-1820, 1993.
34. Ogawa, M., Nishiura, T., Oritani, K., Yoshida, H., Yoshimura, M., Okajima, Y., Ishikawa, J., Hashimoto, K., Matsumura, I., Tomiyama, Y., and Matsuzawa, Y. Cytokines prevent dexamethasone-induced apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways in a new multiple myeloma cell line. Cancer Res., 60: 4262-4269, 2000.
35. Mitsiades, C. S., Mitsiades, N., Poulaki, V., Schlossman, R., Akiyama, M., Chauhan, D., Hideshima, T., Treon, S. P., Munshi, N. C., Richardson, P. G., and Anderson, K. C. Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-I/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene, 21: 5673-5683, 2002.
36. Gupta, D., Treon, S. P., Shima, Y., Hideshima, T., Podar, K., Tai, Y. T., Lin, B., Lentzch, S., Davies, F. E., Chauhan, D., Schlossman, R. L., Richardson, P., Ralph, P., Wu, L., Payvandi, F., Muller, G., Stirling, D. I., and Anderson, K. C. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia (Baltimore), 15: 1950-1961, 2001.
37. Hideshima, T., Chauhan, D., Schlossman, R., Richardson, P., and Anderson, K. C. The role of tumor necrosis factor α in the pathogenesis of human multiple myeloma: therapeutic applications. Oncogene, 20: 4519-4527, 2001.
38. Hideshima, T., Chauhan, D., Richardson, P., Mitsiades, C., Mitsiades, N., Hayashi, T., Munshi, N., Dang, L., Castro, A., Palombella, V., Adams, J., and Anderson, K. C. NF-κB as a therapeutic target in multiple myeloma. J. Biol. Chem., 277: 16639-16647, 2002.
39. Hideshima, T., Akiyama, M., Hayashi, T., Richardson, P., Schlossman, R., Chauhan, D., and Anderson, K. C. Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood, 101: 703-705, 2003.
40. Uchiyama, H., Barut, B. A., Mohrbacher, A. F., Chauhan, D., and Anderson, K. C. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood, 82: 3712-3720, 1993.
41. Han, Z., Boyle, D. L., Chang, L., Bennett, B., Karin, M., Yang, L., Manning, A. M., and Firestein, G. S. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J. Clin. Investig., 108: 73-81, 2001.
42. Bennett, B. L., Sasaki, D. T., Murray, B. W., O'Leary, E. C., Sakata, S. T., Xu, W., Leisten, J. C., Motiwala, A., Pierce, S., Satoh, Y., Bhagwat, S. S., Manning, A. M., and Anderson, D. W. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. USA, 98: 13681-13686, 2001.
43. Hideshima, T., Mitsiades, C., Akiyama, M., Hayashi, T., Chauhan, D., Richardson, P., Schlossman, R., Munshi, N., Mitsiades, N., and Anderson, K. C. Molecular mechanisms mediating anti-myeloma activity of proteasome inhibitor PS-341. Blood, 101: 1530-1534, 2003.
44. Chauhan, D., Pandey, P., Ogata, A., Teoh, G., Treon, S., Urashima, M., Kharbanda, S., and Anderson, K. C. Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism. Oncogene, 15: 837-843, 1997.
45. Chauhan, D., Guilan, L., Hideshima, T., Podar, K., Mitsiades, C., Mitsiades, N., Munshi, N., Kharbanda, S., and Anderson, K. C. JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells. J. Biol. Chem., 278: 17593-17596, 2003.
46. Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Richardson, P. G., Hideshima, T., Munshi, N. C., Treon, S. P., and Anderson, K. C. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood, 99: 4525-4530, 2002.
47. Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Gu, X., Bailey, C., Joseph, M., Libermann, T. A., Treon, S. P., Munshi, N. C., Richardson, P. G., Hideshima, T., and Anderson, K. C. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc. Natl. Acad. Sci. USA, 99: 14374-14379, 2002.
48. Chauhan, D., Hideshima, T., Rosen, S., Reed, J. C., Kharbanda, S., and Anderson, K. C. Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells. J. Biol. Chem., 276: 24453-24456, 2001.
49. Hayashi, T., Hideshima, T., Akiyama, M., Richardson, P., Schlossman, R. L., Chauhan, D., Munshi, N. C., Waxman, S., and Anderson, K. C. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol. Cancer Ther., 1: 851-860, 2002.
50. Zhou, H., and Salvesen, G. S. Activation of pro-caspase-7 by serine proteases includes a non-canonical specificity. Biochem. J., 324: 361-364, 1997.
51. Harris, J. L., Peterson, E. P., Hudig, D., Thornberry, N. A., and Craik, C. S. Definition and redesign of the extended substrate specificity of granzyme B. J. Biol. Chem., 273: 27364-27373, 1998.
52. Bonham, L., Leung, D., White, T., Hollenback, D., Klein, P., Tulinski, J., Coon, M., de Vries, P., and Singer, J. W. Lysophosphatidic acid acyltransferase-β: a novel target for induction of tumor cell apoptosis through inhibition of kinase signalling pathways. Expert. Opin. Ther. Targets, 7: 643-661, 2003.
53. Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernandez-Luna, J. L., Nunez, G., Dalton, W. S., and Jove, R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity, 10: 105-115, 1999.
54. Puthier, D., Bataille, R., and Amiot, M. IL-6 up-regulates Mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur. J. Immunol., 29: 3945-3950, 1999.
55. Wei, L. H., Kuo, M. L., Chen, C. A., Chou, C. H., Cheng, W. F., Chang, M. C., Su, J. L., and Hsieh, C. Y. The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a P13-K/Akt pathway. Oncogene, 20: 5799-5809, 2001.
56. Epling-Burnette, P. K., Liu, J. H., Catlett-Falcone, R., Turkson, J., Oshiro, M., Kothapalli, R., Li, Y., Wang, J. M., Yang-Yen, H. F., Karras, J., Jove, R., and Loughran, T. P., Jr. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J. Clin. Investig., 107: 351-362, 2001.
57. Gupta, D., Podar, K., Lin, B., Hideshima, T., Akiyama, M., LeBlanc, R., Catley, L., Mitsiades, N., Mitsiades, C., Chauhan, D., Munshi, N. C., and Anderson, K. C. β-Lapachone, a novel plant product overcomes drug resistance in human multiple myeloma cells. Exp. Hematol., 30: 711-720, 2002.
58. Chauhan, D., Catley, L., Sattler, M., Li, G., Hideshima, T., LeBlanc, R., Gupta, D., Richardson, P., Schlossman, R. L., Podar, K., Munshi, N., and Anderson, K. 2-Methoxyestradiol (2ME2) acts directly on tumor cells and in the bone marrow microenvironment to overcome drug resistance in multiple myeloma. Blood, 100: 2187-2194, 2002.
59. Gabai, V. L., Meriin, A. B., Yaglom, J. A., Volloch, V. Z., and Sherman, M. Y. Role of Hsp70 in regulation of stress-kinase JNK: implications in apoptosis and aging. FEBS Lett., 438: 1-4, 1998.
60. Xu, F. H., Sharma, S., Gardner, A., Tu, Y., Raitano, A., Sawyers, C., and Lichtenstein, A. Interleukin-6-induced inhibition of multiple myeloma cell apoptosis: support for the hypothesis that protection is mediated via inhibition of the JNK/SAPK pathway. Blood, 92: 241-251, 1998.
61. Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Richardson, P. G., Hideshima, T., Munshi, N., Treon, S. P., and Anderson, K. C. Biologic sequelae of nuclear factor-κB blockade in multiple myeloma: therapeutic applications. Blood, 99: 4079-4086, 2002.
62. Chauhan, D., Uchiyama, H., Akbarali, Y., Urashima, M., Yamamoto, K., Libermann, T. A., and Anderson, K. C. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κB. Blood, 87: 1104-1112, 1996.
63. Akiyama, M., Hideshima, T., Hayashi, T., Tai, Y. T., Mitsiades, C. S., Mitsiades, N., Chauhan, D., Richardson, P., Munshi, N., and Anderson, K. C. Nuclear factor-κB p65 mediates tumor necrosis factor α-induced nuclear translocation of telomerase reverse transcriptase protein. Cancer Res., 63: 18-21, 2003.
64. Anrather, J., Csizmadia, V., Soares, M. P., and Winkler, H. Regulation of NF-κB RelA phosphorylation and transcription activity by p21 (ras) and protein kinase Cζ in primary endothelial cells. J. Biol. Chem., 274: 13594-13603, 1999.
65. Martin, A. G., San-Antonio, B., and Fresno, M. Regulation of nuclear factor κB transactivation. Implication of phosphatidylinositol 3-kinase and protein kinase Cζ in c-rel activation by tumor necrosis factor α. J. Biol. Chem., 276: 15840-15849, 2001.
66. Rahman, A., Anwar, K. N., and Malik, A. B. Protein kinase Cζ mediates TNF-α-induced ICAM-I gene transcription in endothelial cells. Am. J. Physiol. Cell Physiol., 279: 906-914, 2000.
67. Limatola, C., Schaap, P., Moolenaar, W. H., and van Blitterswijk, W. J. Phosphatidic acid activation of protein kinase C-ζ overexpressed in COS cells: comparison with other protein kinase C isotypes and other acidic lipids. Biochem. J., 304: 1001-1008, 1994.
68. Teoh, G., and Anderson, K. C. Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematol. Oncol. Clin. North Am., 11: 27-42, 1997.
69. Anderson, K. C. Targeted therapy for multiple myeloma. Semin. Hematol., 38: 286-297, 2001.
70. Dankbar, B., Padro, T., Leo, R., Feldmann, B., Kropff, M., Mesters, R. M., Serve, H., Berdel, W. E., and Kienast, J. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood, 95: 2630-2636, 2000.